Informazione: Questa è una versione obsoleta del modello di dati. È possibile accedere alla versione corrente tramite Versioni a sinistra.
Informazione:
Errore:
ID
16622
Descrizione
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Screening Assessments
collegamento
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords
versioni (2)
- 27/07/16 27/07/16 -
- 01/08/16 01/08/16 -
Caricato su
27 luglio 2016
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT) NCT00373425
Test Screening Assessments NCT00373425
- StudyEvent: ODM
Similar models
Test Screening Assessments NCT00373425
- StudyEvent: ODM
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Site number
Item
Site Number
integer
C0018704 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
Patient Number
Item
Patient Number
integer
C1830427 (UMLS CUI [1])
Patient Initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
CL Item
Male (1)
CL Item
Female (2)
CL Item
Hispanic/Latino (1)
CL Item
Not Hispanic/Latino (2)
CL Item
American Indian/Alaska Native (1)
CL Item
Asian: Far East (2)
CL Item
Asian: Southeast Asia (3)
CL Item
Asian: Indian Subcontinent (4)
CL Item
Black (5)
CL Item
Native Hawaiian/Pacific Islander (6)
CL Item
White (7)
CL Item
Other (8)
Race
Item
If other, specify
text
C0034510 (UMLS CUI [1])
Inclusion Criteria
Item
Did the patient meet all of the screening inclusion criteria?
boolean
C1512693 (UMLS CUI [1])
Inclusion Criteria
Item
lf No, which was/were not met? Inclusion Letter(s):
text
C1512693 (UMLS CUI [1])
Exclusion Criteria
Item
Did the patient meet any of the screening exclusion criteria?
boolean
C0680251 (UMLS CUI [1])
Exclusion Criteria
Item
If Yes, which was/were met? Exclusion Letter(s):
text
C0680251 (UMLS CUI [1])
Item
lf any screening eligibility criteria were not met, was an exemption granted by OSI?
integer
C1516637 (UMLS CUI [1,1])
C2348482 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
Code List
lf any screening eligibility criteria were not met, was an exemption granted by OSI?
CL Item
Yes (1)
CL Item
No (2)
CL Item
NA (3)
Date screening consent was signed
Item
Date screening consent was signed:
date
C0011008 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,2])
IVRS Screening Number
Item
IVRS Screening Number
text
C1710477 (UMLS CUI [1])
Inclusion Criteria
Item
Did the patient meet all of the treatment inclusion criteria?
boolean
C1512693 (UMLS CUI [1])
Inclusion Criteria
Item
lf No, which was/were not met? Inclusion Number(s):
text
C1512693 (UMLS CUI [1])
Exclusion Criteria
Item
Did the patient meet any of the treatment exclusion criteria?
boolean
C0680251 (UMLS CUI [1])
Exclusion Criteria
Item
If Yes, which was/were met? Exclusion Number(s):
text
C0680251 (UMLS CUI [1])
Item
lf any treatment eligibility criteria were not met, was an exemption granted by OSI?
integer
C1516637 (UMLS CUI [1,1])
C2348482 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
Code List
lf any treatment eligibility criteria were not met, was an exemption granted by OSI?
CL Item
Yes (1)
CL Item
No (2)
CL Item
NA (3)
Date main study consent was signed
Item
Date main study consent was signed:
date
C0011008 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,2])
Randomization Date
Item
Date randomized through IVRS (Study drug therapy must start within 5 days of randomization.):
date
C0011008 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
C0034656 (UMLS CUI [1,2])